In 2003, the Anti-TNF-α Therapy Against Congestive Heart Failure (ATTACH) trial enrolled 150 patients with HF (NYHA class III, EF < 35%), who were randomized to receive either a placebo, infliximab 5 mg/kg, or infliximab 10 mg/kg via IV infusion at weeks 0, 2, and 6. This evidence concerns the gene TNF and hydrops fetalis.